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Interstitial del(5q) was first reported as a type of refractory anemia with characteristic clinical features; female 
predominance (unlike other MDS), macrocytosis, erythroid hypoplasia, frequent thrombocytosis and 
dysmegakaryopoiesis. It is one of the most common structural rearrangements in MDS (10%), seen as an isolated 
abnormality or with additional karyotypic anomalies. It is also observed in AML, with important prognostic 
significance. 
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The World Health Organization (WHO) defined the 5q-  
syndrome as a specific type of MDS, restricting 
diagnosis to the cases with isolated interstitial del(5q), 
without excess blasts in the bone marrow (<5%). It also 
defined a new category, therapy-related MDS/AML, 
excluding cases with a history of previous 
chemotherapy from 5q- syndrome MDS. 
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Clinics 
As described above, cases of MDS with isolated 
del(5q) show female predominance (M:F=1:1.5-4), 
anemia, macrocytosis, normal or moderately decreased 
WBC, normal or moderately decreased platelet count, 
and dysmegakaryopoiesis. 
Treatment 
Supportive care including RBC transfusion for anemia 
is the mainstay of treatment. It is not infrequent that 
transfusions are needed for years, causing iron 
overload, and increasing the risk of blood-borne 
infections. Anemia of 5q- syndrome does not respond 
well to erythropoietin. Leanalidomide, a Thalidomide 
derivative, has been investigated for treatment of MDS 
with 5q-. Lenalidomide has immunomodulatory 
properties, including the suppression of pro-
inflammatory cytokine production by monocytes, 
enhancement of T-cell and NK-cell activation, and 
inhibition of angiogenesis. In Phase II trials in 
transfusion-dependent MDS with 5q-, 168 patients 
were enrolled, of whom 76% had isolated 5q- and 29% 
had the 5q- syndrome. Transfusion independence was 
obtained in 67%. A complete cytogenetic response was 
achieved in 45% of patients. Cytogenetic response rate 
was not significantly different in isolated del(5q), 
del(5q) + 1 and del(5q) + >1 additional chromosome 
abnormalities. Although the results of lenalidomide 
treatment seem promising, it is not yet clear if the 
treatment will affect the natural disease course and 
prolongs survival. 
Prognosis 
The impact of lenalidomide on the prognosis of MDS 
patients with 5q- is unknown at this point. Progression 
to AML is rare (10%). With the supportive therapy, the 
prognosis of 5q- syndrome is favorable, with reported 
median survival ranging from 53 to 146 months. MDS 
patients with 5q- plus one additional chromosome 
abnormality seem to have significantly shorter survival 
(with exception of loss of the Y chromosome). MDS 
with 5q- as part of a complex karyotype (3 or more 
abnormalities) have an unfavorable prognosis. 
Disease 
AML (Acute Myeloid Leukemia). 
Clinics 
Deletion of 5q can be observed in both de novo and 
therapy related AML. It is also seen as monosomy 5. In 
AML, 5q deletion is usually associated with a complex 
karyotype. 
Prognosis 
Prognosis of AML with 5q-/-5 is generally unfavorable, 
associated with rapid disease progression and poor 
outcome and survival, especially when it is seen as a 





The most commonly observed interstitial deletions are 
del(5)(q13q31), del(5)(q13q33), and del(5)(q22q33), 
forming a commonly deleted region (CDR) at 5q31-
q32. 
Cytogenetics molecular 
The CDR is the approximately 1.5 Mb interval between 
D5S413 and GLRA1 gene, containing around 40 genes. 
No cases of 5q- syndrome have been reported to have 
biallelic deletion within the CDR, and no point 
mutations have been found in the genes in the region. 
Recently, it is suggested that haploinsufficienty (a gene 
dosage effect) of one or more of the genes mapping to 
the CDR is the pathogenetic basis of the 5q- syndrome. 
Ebert et al. demonstrated that impaired function of the 
ribosomal subunit protein RPS14 recapitulated the 
characteristic phenotype of the 5q- syndrome, a severe 
decrease in the production of erythroid cells with 
relative preservation of megakaryocytic cells, in normal 
CD34+ human hematopoietic progenitor cells. In 
addition, forced expression of RPS14 rescued the 
disease phenotype in patient-derived bone marrow 
cells. 
Germline heterozygous mutations for two other 
ribosomal proteins, RPS19 and RPS24, have recently 
been described in the congenital disorder known as 
Diamond-Blackfan anemia. The conge-nital anemia is 
characterized by sever anemia, macrocytosis, relative 
preservation of the platelet and neutrophil count, 
erythroid hypoplasia in the bone marrow and an 
increased risk of leukemia. The erythroid specificity of 
5q- syndrome and Diamond-Blackfan anemia in 
ribosomal expression is noteworthy. 
Additional anomalies 
By definition, an interstitial deletion of 5q must be the 
sole abnormality for 5q- syndrome. However, 5q 
deletion can be seen with other accompanying 
abnormalities. Review of the recent Mayo Clinic cases 
shows that major abnormalities include -7, +8, -20, 
20q-, -13/13q-, and abnormalities in 12p, in the 
descending order. 
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